Acute Lymphoid Leukemia
Conditions
Brief summary
To assess the efficacy (in terms of response rate and duration) of the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity \[A3B1\] conjugated to the 4-aBB and CD3z co-stimulatory regions) in patients with resistant or refractory CD19+ acute lymphoid leukemia
Interventions
DRUGARI-0001 cells
Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
Sponsors
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Instituto de Salud Carlos III
Sara V. Latorre
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnoses of CD19+ acute lymphoid leukemia, with a life expectancy of less than 2 years that meet the following conditions: 1. Relapsed/refractory not candidate for transplantation (due to associated diseases or absence of donor) 2. in allogenic post-transplant relapse. 2. Measurable disease understood as the presence of measurable residual disease by flow cytometry in bone marrow or peripheral blood 3. Age less than 70 years (from 18 to 70). 4. ECOG functional status from 0 to 2 5. Life expectancy of at least 3 months. 6. Adequate venous access to perform a lymphapheresis. Absence of contraindications for it. 7. Signature of informed consent.
Exclusion criteria
1. Treatment with any experimental or non-marketed substance within four weeks prior to recruitment, or actively participating in another therapeutic trial. 2. Previous treatment with CART therapy (commercial or experimental) 3. Diagnosis of another neoplasm, past or present. Patients may be included in complete remission for more than 3 years, or have a history of non-melanoma skin cancer or in-situ carcinoma resected completely. 4. Relief of central nervous system (CNS-3) at the time of inclusion. Inclusion will be permitted in patients with a lower grade (CNS-2) or CNS-3 who have responded to intrathecal chemotherapy. 5. Isolated extramedullary involvement (i.e. in the absence of minimal residual disease in peripheral blood, bone marrow, or cerebrospinal fluid) 6. Early relapse after transplantation (less than 3 months for mononuclear cell apheresis, less than 6 months for infusion of ARI-0001) 7. Active immunosuppressive treatment for graft-versus-host disease and other diseases. The use of corticosteroids to control leukaemia at the time of inclusion should be limited as much as possible and should be discontinued prior to infusion of ARI-0001 cells. 8. Active infection requiring systemic medical treatment such as chronic kidney infection, chronic lung infection or tuberculosis. 9. HIV infection. 10. Positive serology for hepatitis B, defined as a positive test for HBsAg. In addition, if the patient is HBsAg negative but has anti-HBc antibodies it will be necessary to perform a DNA test of the hepatitis B virus, and if the result is positive the patient will be excluded 11. Positive serology for hepatitis C, defined as a positive test for anti-VHC antibodies confirmed by RIBA 12. Concurrent uncontrolled medical illnesses including cardiac, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological or psychiatric diseases that in the opinion of the investigator are potential risk factors to the patient. 13. Severe organ involvement, defined as cardiac ejection fraction \<40%; DLCO \<40%; calculated glomerular filtrate \<30 ml/min; or bilirubin \> 3 times the upper limit of normality (unless Gilbert syndrome). 14. Pregnant or lactating women. Woman of childbearing potential should have a negative pregnancy test in the screening phase. 15. Women of childbearing potential, including those whose last menstrual cycle was in the year prior to screening, who are unable or unwilling to use highly effective contraceptive methods\* from the start of the study to the completion of the study. 16. Men who cannot or do not wish to use highly effective contraceptive methods\* from the beginning of the study until the end of the study \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response rate | 20 days after infusion | • Response rate with measurable residual disease negative by multiparametric flow cytometry |
Countries
Spain
Outcome results
None listed